Folia Neuropathologica
eISSN: 1509-572x
ISSN: 1641-4640
Folia Neuropathologica
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
4/2025
vol. 63
 
Share:
Send email
Share:
Review paper

Immune reconstitution for the treatment of myasthenia gravis: the focus on cladribine

Konrad Rejdak
1
,
Dariusz Baranowski
1
,
Paweł Grieb
2

  1. Department of Neurology, Medical University of Lublin, Lublin, Poland
  2. Department of Experimental Pharmacology, Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland
Folia Neuropathol 2025; 63 (4): 327-334
DOI: https://doi.org/10.5114/fn.2025.158395
Online publish date: 2025/12/22
Article file
- Immune.pdf  [0.23 MB]
Get citation
 
PlumX metrics:
 
1. Agmon-Levin N, Lian Z, Shoenfeld Y. Explosion of autoimmune diseases and the mosaic of old and novel factors. Cell Mol Immunol 2011; 8: 189-192.
2. Al Sharoqi IA, Aljumah M, Bohlega S, Boz C, Daif A, El-Koussa S, Inshasi J, Kurtuncu M, Müller T, Retief C, Sahraian MA, Shaygannejad V, Slassi I, Taha K, Zakaria M, Sørensen PS. Immune reconstitution therapy or continuous immunosuppression for the management of active relapsing-remitting multiple sclerosis patients? A narrative review. Neurol Ther 2020; 9: 55-66.
3. Alexander T, Greco R. Hematopoietic stem cell transplantation and cellular therapies for autoimmune diseases: overview and future considerations from the Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 2022; 57: 1055-1062.
4. Berrih-Aknin S, Frenkian-Cuvelier M, Eymard B. Diagnostic and clinical classification of autoimmune myasthenia gravis. J Autoimmun 2014; 48-49: 143-148.
5. Bryant A, Atkins H, Pringle CE, Allan D, Anstee G, Bence-Bruckler I, Hamelin L, Hodgins M, Hopkins H, Huebsch L, McDiarmid S, Sabloff M, Sheppard D, Tay J, Bredeson C. Myasthenia gravis treated with autologous hematopoietic stem cell transplantation. JAMA Neurol 2016; 73: 652-658.
6. Carballido JM, Regairaz C, Rauld C, Raad L, Picard D, Kammüller M. The emerging jamboree of transformative therapies for autoimmune diseases. Front Immunol 2020; 11: 472.
7. Cooper GS, Stroehla BC. The epidemiology of autoimmune diseases. Autoimmun Rev 2003; 2: 119-125.
8. Drachman DB, Angus CW, Adams RN, Kao I. Effect of myasthenic patients’ immunoglobulin on acetylcholine receptor turnover: selectivity of degradation process. Proc Natl Acad Sci U S A 1978; 75: 3422-3426.
9. Dresser L, Wlodarski R,Rezania K, Soliven B. Myasthenia gravis: Epidemiology, pathophysiology and clinical manifestations.
10. J Clin Med 2021; 10: 2235.
11. Engel AG, Arahata K. The membrane attack complex of complement at the endplate in myasthenia gravis. Ann N Y Acad Sci 1987; 505: 326-332.
12. Grieb P, Ryba M, Stelmasiak Z, Nowicki J, Solski J, Jakubowska B. Cladribine treatment of multiple sclerosis. Lancet 1994; 344: 538.
13. Grieb P, Stelmasiak Z, Solski J, Nowicki J, Jakubowska B, Ryba M. Effect of repeated treatments with cladribine (2-chlorodeoxyadenosine) on blood counts in multiple sclerosis patients. Arch Immunol Ther Exp (Warsz) 1995; 43: 323-327.
14. Grieb P, Stelmasiak Z. Treatment of multiple sclerosis with cladribine (2-CDA), a new immunosuppressant agent. Theoretical basis and preliminary results. Neurol Neurochir Pol 1995; 29: 69-76.
15. Jordan A, Freimer M. Recent advances in understanding and managing myasthenia gravis. F1000Res 2018; 7: F1000 Faculty Rev-1727.
16. Kaminski HJ, Sikorski P, Coronel SI, Kusner LL. Myasthenia gravis: the future is here. J Clin Invest 2024; 134: e179742.
17. Krance R, Brenner M. BMT beats autoimmune disease. Nat Med 1998; 4: 153-155.
18. Lin Y, Chang T, Lin J, Sun C, Wei C, Zhao J, Liu R, Yang K, Li Z. Regulatory B cells are decreased and functionally impaired in myasthenia gravis patients. Front Neurol 2022; 13: 808322.
19. Lünemann JD, Ruck T, Muraro PA, Bar-Or A, Wiendl H. Immune reconstitution therapies: concepts for durable remission in multiple sclerosis. Nat Rev Neurol 2020; 16: 56-62.
20. Rejdak K, James F. Howard JF, Cutter G, O’Connor K, Dimachkie M, Palace J, Meisel A, Mantegazza R, Nolting A, Gopalakrishnan S, Le Bolay C, Javor A, Alexandri N, Jack D, Kaminski H. Oral cladribine capsules for generalized myasthenia gravis: design of the actively recruiting phase 3 MyClad study (P1-11.013) Neurology 2025; 104 (7, Supplement 1): 1608.
21. Rejdak K, Stelmasiak Z, Grieb P. Cladribine induces long lasting oligoclonal bands disappearance in relapsing multiple sclerosis patients: 10-year observational study. Mult Scler Relat Disord 2019; 27: 117-120.
22. Rejdak K, Szklener S, Korchut A, Baranowski D. Cladribine in myasthenia gravis: a pilot open-label study. Eur J Neurol 2020; 27: 586-589.
23. Rejdak K, Zasybska A, Pietruczuk A, Baranowski D, Szklener S, Kaczmarek M, Stelmasiak Z. Long-term safety and efficacy of subcutaneous cladribine used in increased dosage in patients with relapsing multiple sclerosis: 20-year observational study. J Clin Med 2021; 10: 5207.
24. Rosenblum MD, Gratz IK, Paw JS, Abbas AK. Treating human autoimmunity: current practice and future prospects. Sci Transl Med 2012; 4: 125sr1.
25. Schmierer K, Wiendl H, Barkhof F, Montalban X, Achiron A, Derfuss T, Chan A, Hodgkinson S, Prat A, Leocani L, Sellebjerg F, Vermersch P, Jin H, Sponton L, Chudecka A, Gardner L, De Stefano N. Clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS Study. Ther Adv Neurol Disord 2025; 18: 17562864251351760.
26. Smets I, Wokke B, Smolders J. Should anti-CD20 be used as an immune reconstitution therapy? Mult Scler 2023; 29: 308-310.
27. Stelmasiak Z, Solski J, Nowicki J, Jakubowska B, Ryba M, Grieb P. Effect of parenteral cladribine on relapse rates in patients with relapsing forms of multiple sclerosis: results of a 2-year, double-blind, placebo-controlled, crossover study. Mult Scler 2009; 15: 767-770.
28. Stüve O, Leussink VI, Fröhlich R, Hemmer B, Hartung HP, Menge T, Kieseier BC. Long-term B-lymphocyte depletion with rituximab in patients with relapsing-remitting multiple sclerosis. Arch Neurol 2009; 66: 259-261.
29. Stüve O, Leussink VI, Fröhlich R, Hemmer B, Hartung HP, Menge T, Kieseier BC. Tao MH, Canfield SM, Morrison SL. The differential ability of human IgG1 and IgG4 to activate complement is determined by the COOH-terminal sequence of the CH2 domain. J Exp Med 1991; 173: 1025-1028.
30. Thiruppathi M, Rowin J, Ganesh B, Sheng JR, Prabhakar BS, Meriggioli MN. Impaired regulatory function in circulating CD4(+)CD25(high)CD127(low/-) T cells in patients with myasthenia gravis. Clin Immunol 2012; 145: 209-223.
31. Uysal SP, Morren JA. Promising therapies for the treatment of myasthenia gravis. Expert Opin Pharmacother 2024; 25: 395-408.
32. Wang J, Xiao Y, Zhang K, Luo B, Shen C. Introducing autoimmunity at the synapse by a novel animal model of experimental autoimmune myasthenia gravis. Neuroscience 2018; 374: 264-270.
Copyright: © 2025 Mossakowski Medical Research Centre Polish Academy of Sciences and the Polish Association of Neuropathologists. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
  
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2026 Termedia Sp. z o.o.
Developed by Bentus.